96 Tests PN: B213458

Components:

45x Ab-conjugated beads (S4P12 - Mouse sTNFRI Ab-bead). PN: B213458A. One vial containing 100 µL of anti-mouse sTNFR1 conjugated to AimPlex Bead S4P12.

25x Biotin-detection Ab (Mouse sTNFRI Biotin-dAb). PN: B213458B. One vial containing 100 µL of biotinylated anti-mouse sTNFR1.

Lyophilized Standard Mix - Mouse Group 5 Panel B, 10-Plex. PN: MG5010B. One vial containing lyophilized recombinant sCD27, sCD105, sIFNγR1, sTNFR1, sTNFRII,  sTWEAK-R, sVEGFR1, sVEGFR2, sIL-1R1, and sRAGE.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Mouse TNFR1/sTNFRSF1A/sCD120a. Can be multiplexed with other analytes in Mouse Group 5. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage: 2-8 C in the dark

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Mouse Group 5: Negligible

  • Sample volume: 15 µL/test

Description:

Tumor necrosis factor receptor 1 (TNF R1), also known as tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) and CD120a, is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFα). Germline mutations of the extracellular domains of this receptor were found to be associated with the human genetic disorder called tumor necrosis factor associated periodic syndrome (TRAPS) or periodic fever syndrome. Impaired receptor clearance is thought to be a mechanism of the disease. Mutations in the TNFRSF1A gene is associated with elevated risk of multiple sclerosis. Serum levels of TNFRSF1A are elevated in schizophrenia and bipolar disorder, and high levels are associated with more severe psychotic symptoms. High serum levels are also associated with cognitive impairment and dementia. Diseases associated with TNFRSF1A include multiple sclerosis 5 and periodic fever.

References:

  1. Baker E, Chen LZ, Smith CA, Callen DF, Goodwin R, Sutherland GR (November 1991). "Chromosomal location of the human tumor necrosis factor receptor genes". Cytogenet Cell Genet 57 (2–3): 117–8. doi:10.1159/000133127. PMID 1655358.

  2. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH, Gatanaga T, Granger GA, Lentz R, Raab H, et al. (June 1990). "Molecular cloning and expression of a receptor for human tumor necrosis factor". Cell 61 (2): 361–70. doi:10.1016/0092-8674(90)90816-W. PMID 2158863.

  3. Offermanns, Stefan; Rosenthal, Walter (2008). Encyclopedia of Molecular Pharmacology, Vol. 1 (2nd ed.). Heidelberg, Germany: Springer. p. 1248.

  4. Kümpfel T, Hohlfeld R (October 2009). "Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosis". Nat Rev Neurol 5 (10): 528–9. doi:10.1038/nrneurol.2009.154. PMID 19